Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus

Neurochemical Research

Volumn 41, Issue 5, 2016, Pages 1192-1199

  Hong, Yan ^a   Shen, Chao ^a   Yin, Qingqing ^a   Sun, Menghan ^a   Ma, Yingjuan ^a   Liu, Xueping ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Advanced glycation end product; Alzheimer s disease; Amyloid ; FPS ZM1; Inflammation; Oxidative stress; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FPS ZM 1; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AGER PROTEIN, RAT; AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN (11-40); ANTIOXIDANT; BENZAMIDE DERIVATIVE; CYTOKINE; FPS-ZM1; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ASSAY; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCAPE BEHAVIOR; HIPPOCAMPUS; INFLAMMATION; LATENT PERIOD; LIPID PEROXIDATION ASSAY; MALE; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RAT; RAT MODEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; COGNITION DISORDERS; DRUG EFFECTS; MAZE TEST; MEMORY; METABOLISM; PSYCHOLOGY; WISTAR RAT;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BENZAMIDES; COGNITION DISORDERS; CYTOKINES; GLYCOSYLATION END PRODUCTS, ADVANCED; HIPPOCAMPUS; INFLAMMATION; MALE; MAZE LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RATS, WISTAR;

EID: 84953287235     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-015-1814-8     Document Type: Article

References (38)

1. Ferrer I (2012) Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 97(1):38–51
2. Verri M, Pastoris O, Dossena M (2011) Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease. Int J Immunopathol Pharmacol 25(2):345–353
3. Takeuchi M, Kikuchi S, Sasaki N (2004) Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr Alzheimer Res 1(1):39–46
4. Ko SY, Lin YP, Lin YS (2010) Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49(3):474–480
5. Choi BR, Cho WH, Kim J (2014) Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer’s disease. Exp Mol Med 46(2):e75
6. Srikanth V, Maczurek A, Phan T (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32(5):763–777
7. Koch M, Chitayat S, Dattilo BM (2010) Structural basis for ligand recognition and activation of RAGE. Structure 18(10):1342–1352
8. Franke S, Siggelkow H, Wolf G (2007) Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113(3):154–161
9. Slowik A, Merres J, Elfgen A (2012) Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)-and amyloid beta 1-42-induced signal transduction in glial cells. Mol Neurodegener 7(1):55
10. Fang F, Lue LF, Yan S (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 24(4):1043–1055
11. Chen CH, Zhou W, Liu S (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol 15(1):77–90
12. Tobon-Velasco JC, Cuevas E, Torres-Ramos MA (2014) Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets 13(9):1615–1626
13. Yan R, Vassar R (2014) Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol 13(3):319–329
14. Deane R, Singh I, Sagare AP (2012) A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377
15. JJ JJ, Cacabelos R (1998) β-Amyloid (1–40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol 95(5):455–465
16. Hong Y, Hou L, Hou XY, Liu XP (2015) Ectogenic AGEs up-regulate amyloid-β in rat hippocampus through RAGE–CTGF pathway (in preparation)
17. Collison KS, Makhoul NJ, Zaidi MZ (2012) Gender dimorphism in aspartame-induced impairment of spatial cognition and insulin sensitivity. PLoS ONE 7(4):e31570
18. Siqueira IR, Fochesatto C, da Silva Torres IL (2005) Aging affects oxidative state in hippocampus, hypothalamus and adrenal glands of Wistar rats. Life Sci 78(3):271–278
19. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302–310
20. Winterbourn CC, Hawkins R, Brian M (1975) The estimation of red cell superoxide dismutase activity. J Lab Clin Med 85(2):337–341
21. Jollow D, Mitchell J, Na Zampaglione (1974) Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11(3):151–169
22. Hafeman D, Sunde R, Hoekstra W (1974) Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr 104(5):580–587
23. Arancio O, Zhang HP, Chen X (2004) RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J 23(20):4096–4105
24. Lan Z, Liu J, Chen L (2012) Danggui-Shaoyao-San ameliorates cognition deficits and attenuates oxidative stress-related neuronal apoptosis in d-galactose-induced senescent mice. J Ethnopharmacol 141(1):386–395
25. Cai ZY, Liu NN,Wang CL,Qin BY, Zhou YJ, Xiao M, Chang LY, Yan LJ, Zhao B (2015) Role of RAGE in Alzheimer’s disease. Cell Mol Neurobiol. doi:10.1007/s10571-015-0233-3
26. Smith MA, Monnier VM, Sayre LM, Perry G (1995) Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport 6:1595–1596
27. Thome J, Kornhuber J, Munch G, Schinzel R, Taneli Y, Zielke B, Rosler M, Riederer P (1996) New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs). Nervenarzt 67:924–929
28. Guglielmotto M, Aragno M, Tamagno E (2012) AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 33(1):196.e113–196.e127
29. Mincheva-Tasheva S, Soler RM (2013) NF-κB signaling pathways role in nervous system physiology and pathology. Neuroscientist 19(2):175–194
30. Bourne KZ, Ferrari DC, Lange-Dohna C (2007) Differential regulation of BACE1 promoter activity by nuclear factor-κB in neurons and glia upon exposure to β-amyloid peptides. J Neurosci Res 85(6):1194–1204
31. Paris D, Patel N, Quadros A (2007) Inhibition of Aβ production by NF-κB inhibitors. Neurosci Lett 415(1):11–16
32. Win MT, Yamamoto Y, Munesue S (2012) Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res 2012:894605
33. Lander HM, Tauras JM, Ogiste JS (1997) Activation of the receptor for advanced glycation end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272(28):17810–17814
34. Lue LF, Walker DG, Brachova L (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 171(1):29–45
35. Deane R, Bell R, Sagare A (2009) Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 8(1):16
36. Smith MA, Rottkamp CA, Nunomura A (2000) Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 1502(1):139–144
37. Gu Q, Wang B, Zhang XF, Ma YP (2014) Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats. Eur J Pharmacol 741:186–194
38. Yin QQ, Dong CF, Dong SQ (2012) AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol 32(8):1299–1309